Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2

Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2

Newly emerging SARS-CoV-2 variants may escape monoclonal antibodies (mAbs) and antiviral drugs. By using live virus assays, we assessed the ex vivo inhibition of the B.1 wild-type (WT), delta and omicron BA.1 and BA.2 lineages by post-infusion sera from 40 individuals treated with bamlanivimab/etese...

Full description

Bibliographic Details
Main Authors: Lia Fiaschi, Filippo Dragoni, Elisabetta Schiaroli, Annalisa Bergna, Barbara Rossetti, Federica Giammarino, Camilla Biba, Anna Gidari, Alessia Lai, Cesira Nencioni, Daniela Francisci, Maurizio Zazzi, Ilaria Vicenti
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Viruses
Subjects:
SARS-CoV-2
mAbs
nirmatrelvir
remdesivir
molnupiravir
microneutralization assay
Online Access:https://www.mdpi.com/1999-4915/14/7/1374

Internet

https://www.mdpi.com/1999-4915/14/7/1374

Similar Items